Adicet Bio, Inc. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
Adicet Bio, Inc. (ACET) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2023-03-15
- Adicet Bio, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2022-12-31 was $0.00.
- Adicet Bio, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2022-09-30 was $0.00.
- Adicet Bio, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2021-12-31 was $0.00.
- Adicet Bio, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Adicet Bio, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Adicet Bio, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2021 was $2.75M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $0.00 10-K · filed 2023-03-15 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-10 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $1.75M derived: sum of 3 quarters · filed 2023-03-15 | $2.75M 10-K · filed 2023-03-15 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.75M derived: sum of 2 quarters · filed 2022-11-08 | $2.75M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $1.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $2.75M 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $1.00M 10-Q · filed 2022-05-12 | |||
| 2020-09-30 | $10.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $34.55M derived: sum of 2 quarters · filed 2021-11-10 | $44.98M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $23.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $34.23M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $10.44M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |